The Effect of Efavirenz on the Pharmacokinetics of An Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy HIV-Negative Women

Abstract

Background

Women of childbearing age represent a growing proportion of people living with HIV. Preventing pregnancy is important in HIV-infected women receiving efavirenz as part of their antiretroviral therapy.

Methods

The effects of coadministration of efavirenz (600 mg once daily) on the pharmacokinetics (PK) of the active components (ethinyl estradiol [EE] and 17-deacetyl norgestimate [NGMN]) of Ortho Cyclen® (Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ, USA) were investigated in 28 healthy HIV-negative women. The peak plasma concentration (C_max), area under the concentration–time curve for a dosing interval (AUC_[τ]), and lowest plasma concentration (C_min) for EE and NGMN during cycles of treatment with Ortho Cyclen with and without coadministration of efavirenz were compared. Additionally, a post hoc exploratory analysis was conducted to assess the effect of efavirenz on the PK of an additional progestin, levonorgestrel (LNG).

Results

Exposures to EE were similar during coadministration of efavirenz and Ortho Cyclen to those during administration of Ortho Cyclen alone. Exposures to NGMN were substantially decreased following coadministration of efavirenz and Ortho Cyclen (adjusted geometric means for C_max, AUC_[τ] and C_min decreased by 46%, 64% and 82%, respectively) compared with Ortho Cyclen alone. Consistent with NGMN, LNG exposures were decreased 80–86% by efavirenz.

Conclusions

Although efavirenz had no significant effect on the PK of EE, exposures to the progestin components of Ortho Cyclen, NGMN and LNG, were substantially reduced. The results reinforce the need to use reliable methods of barrier contraception, even when taking oral contraceptives and efavirenz.

References

Heikinheimo

, Lahteenmaki

Contraception and HIV infection in women. Hum Reprod Update 2009; 15: 165–176.

Fakoya

, Lamba

, Mackie

British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008. HIV Med 2008; 9: 681–720.

Hammer

S.M.

, Eron

J.J.

Jr. , Reiss

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel. JAMA 2008; 300: 555–570.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 4, 2009. Department of Health and Human Services (Accessed 10 December 2009.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

Sustiva (efavirenz). US prescribing information 2009. Bristol–Myers Squibb

Princeton, NJ, USA.

Sustiva (efavirenz). Summary of product characteristics 2009. Bristol–Myers Squibb

Uxbridge, UK.

Van Vliet

H.A.

, Grimes

D.A.

, Helmerhorst

F.M.

, Schulz

K.F.

Biphasic versus triphasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006; 3: CD003283.

Maitra

, Kulier

, Bloemenkamp

K.W.

, Helmerhorst

F.M.

, Gulmezoglu

A.M.

Progestogens in combined oral contraceptives for contraception. Cochrane Database Syst Rev 2004; 3: CD004861.

El Ibiary

S.Y.

, Cocohoba

J.M.

Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care 2008; 13: 123–132.

10.

Isentress (raltegravir). US prescribing information 2009. Merck & Co., Inc, Whitehouse Station, NJ, USA.

11.

Kent

U.M.

, Mills

D.E.

, Rajnarayanan

R.V.

, Alworth

W.L.

, Hollenberg

P.F.

Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J Pharmacol Exp Ther 2002; 300: 549–558.

12.

Hammond

G.L.

, Abrams

L.S.

, Creasy

G.W.

, Natarajan

, Allen

J.G.

, Siiteri

P.K.

Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception 2003; 67: 93–99.

13.

Palovaara

, Pelkonen

, Uusitalo

, Lundgren

, Laine

Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 2003; 74: 326–333.

14.

Palovaara

, Kivisto

K.T.

, Tapanainen

, Manninen

, Neuvonen

P.J.

, Laine

Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation. Br J Clin Pharmacol 2000; 50: 333–337.

15.

Belle

D.J.

, Callaghan

J.T.

, Gorski

J.C.

The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol 2002; 53: 67–74.

16.

Balogh

, Gessinger

, Svarovsky

Can oral contraceptive steroids influence the elimination of nifedipine and its primary pryidine metabolite in humans?

Eur J Clin Pharmacol 1998; 54: 729–734.

17.

Kuhnz

, Blode

, Mahler

Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. Contraception 1994; 49: 255–263.

18.

Ortho Tri-Cyclen

L.O.

(norgestimate/ethinyl estradiol). US prescribing information 2008. Ortho-McNeil-Janssen Pharmaceuticals Inc.

Raritan, NJ, USA.

19.

Ortho Cyclen (norgestimate/ethinyl estradiol). US prescribing information 2008. Ortho-McNeil-Janssen Pharmaceuticals Inc.

Raritan, NJ, USA.

20.

US Food and Drug Administration. Guidance for industry: drug interaction studies – study design, data analysis, and implications for dosing and labeling. September 2006. (Accessed 4 December 2009.) Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf.

21.

NIH Clinical Center. Progesterone historical reference ranges. National Institutes of Health. (Updated 20 March 2009. Accessed 4 December 2009.) Available from http://cclnprod.cc.nih.gov/dlm/testguide.nsf/Index/CB26894E1EB28DEF85256BA5005B000E?OpenDocument.

22.

London

R.S.

, Chapdelaine

, Upmalis

, Olson

, Smith

Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand Suppl 1992; 156: 9–14.

23.

Weiss

, Herzog

, Konig

, Storch

C.H.

, Ketabi-Kiyanvash

, Haefeli

W.E.

Induction of multiple drug transporters by efavirenz. J Pharmacol Sci 2009; 109: 242–250.

24.

Josephson

, Bertilsson

, Bottiger

CYP3A induction and inhibition by different antiretroviral regimens refected by changes in plasma 4beta-hydroxycholesterol levels. Eur J Clin Pharmacol 2008; 64: 775–781.

25.

Chu

J.H.

, Gange

S.J.

, Anastos

Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Am J Epidemiol 2005; 161: 881–890.

26.

Cohn

S.E.

, Park

J.G.

, Watts

D.H.

Depomedroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 2007; 81: 222–227.

27.

Nanda

, Amaral

, Hays

, Viscola

M.A.

, Mehta

, Bahamondes

Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril 2008; 90: 965–971.

28.

Watts

D.H.

, Park

J.G.

, Cohn

S.E.

Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception 2008; 77: 84–90.

29.

Matiluko

A.A.

, Soundararjan

, Hogston

Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. J Fam Plann Reprod Health Care 2007; 33: 277–278.